Fecal Microbiota Transfer in Acute Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation.

Autor:	Weber D; Department of Internal Medicine III (Haematology/Oncology), University Hospital Regensburg, Regensburg, Germany., Meedt E; Department of Internal Medicine III (Haematology/Oncology), University Hospital Regensburg, Regensburg, Germany., Poeck H; Department of Internal Medicine III (Haematology/Oncology), University Hospital Regensburg, Regensburg, Germany., Thiele-Orberg E; Department of Internal Medicine III (Haematology/Oncology), University Hospital Regensburg, Regensburg, Germany.; Department of Medicine III, Technical University of Munich (TUM), Klinikum r.d. Isar, Munich, Germany., Hiergeist A; Department for Microbiology and Hygiene, University of Regensburg, Regensburg, Germany., Gessner A; Department for Microbiology and Hygiene, University of Regensburg, Regensburg, Germany., Holler E; Department of Internal Medicine III (Haematology/Oncology), University Hospital Regensburg, Regensburg, Germany.
Jazyk:	angličtina
Zdroj:	Visceral medicine [Visc Med] 2024 Mar 26, pp. 1-6. Date of Electronic Publication: 2024 Mar 26.
DOI:	10.1159/000538303
Abstrakt:	Background: Acute graft-versus-host disease (GvHD) is a major and sometimes lethal complication following allogeneic stem cell transplantation (aSCT). In the last 10 years, a massive loss of microbiota diversity with suppression of commensal bacteria and their protective metabolites has been identified as a major risk factor of GvHD. Summary: Since 2018, several studies have been published showing some efficacy of fecal microbiota transfer (FMT) in aSCT patients. FMT was used (1) to eliminate antibiotic resistant bacteria, (2) to restore microbiota diversity after hematopoietic recovery, or (3) in most cases to treat steroid-resistant GvHD. Overall response rates between 30 and 50% have been reported, but randomized trials are still pending. Newer approaches try to evaluate the role of prophylactic FMT in order to prevent GvHD and other complications. Although aSCT patients are heavily immunosuppressed, no major safety concerns regarding FMT have been reported so far. Key Message: FMT is a promising approach for modulation of GvHD after aSCT and should be further explored in randomized trials. Competing Interests: E. Holler is member of the Scientific Advisory Board of Maat Pharma, Lyon, and Pharmabiome, Zürich. (© 2024 S. Karger AG, Basel.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu